New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:35 EDTALXNAlexion says data confirm long-term safety, efficacy of chronic Soliris therapy
Alexion Pharmaceuticals announced the presentation of new data demonstrating the long-term benefits of Soliris in patients with paroxysmal nocturnal hemoglobinuria, a debilitating, ultra-rare and life-threatening blood disorder. Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome were presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. The company said ten-year data from a large cohort of patients with PNH from the United Kingdom confirm the long-term safety and efficacy of chronic Soliris therapy and demonstrate the impact of Soliris on quality of life. The long-term safety of Soliris was also demonstrated in PNH clinical development trials in which patients were treated continuously with Soliris and followed for up to 5.5 years and other Soliris data was presented as well.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:34 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
Subscribe for More Information
07:33 EDTALXNAlexion names Hallal COO, Carmichael Chief Human Resources Officer
September 14, 2014
17:44 EDTALXNAlexion presents data on pediatric HPP patients treated with asfotase alfa
Alexion Pharmaceuticals announced that researchers presented new data from an integrated analysis of survival from two open-label, Phase 2 studies of asfotase alfa in pediatric patients with hypophosphatasia, HPP, compared with data from a retrospective natural history study of untreated historical control patients matched for age and disease severity. In this analysis, survival in patients with HPP at high risk of death who were treated with asfotase alfa for up to five years was significantly improved compared with untreated historical control patients.These late-breaking results were presented at the American Society for Bone and Mineral Research, ASBMR, 2014 Annual Meeting in Houston, where researchers also presented new data from the ongoing open-label extension phases of two Phase 2 clinical studies in which sustained gains in physical function and reductions in disability and pain were observed in pediatric patients receiving asfotase alfa treatment for up to three years.
September 12, 2014
07:14 EDTALXNAmerican Society for Bone & Mineral Research holds annual meeting
Subscribe for More Information
September 8, 2014
06:31 EDTALXNAlexion announces asfotase alfa granted orphan drug designation in Japan
Subscribe for More Information
September 5, 2014
10:05 EDTALXNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use